Press Releases

Technology focused company streamlines operations while focused on its digital platform

Austin, Texas, June 02, 2024 (GLOBE NEWSWIRE) -- ePac Flexible Packaging, founded in 2016 as the world's first all-digital flexible packaging company, just turned 8 years old in May of this year. So it’s fair to ask: How is ePac doing with its disruptive business model? From 2016 through 2022 ePac consistently grew 50 -100% per year. In 2023 ePac’s growth slowed, but units... (continue reading...)

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1... (continue reading...)

Imagine a world where seeing eyelid surgery results before the surgery are no longer just a dream but a reality. With groundbreaking advancements in technology and 3D facial images, the realm of blepharoplasty is on the brink of a major revolution.

London, United Kingdom Jun 1, 2024 (Issuewire.com) - Ophthalmologist and Oculoplastic Surgeon Mr Ahmad Aziz has come up with a new service through his leading clinic in Central London, known as Eyes Defined. The clinic is... (continue reading...)

SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI), in patients with non-small-cell lung cancer (NSCLC) in a poster presentation at the 60th American Society... (continue reading...)

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both... (continue reading...)